Skip to main content
AstraZeneca Pharma India Ltd. logo

AstraZeneca Pharma India Ltd. — Investor Relations & Filings

Ticker · ASTRAZEN ISIN · INE203A01020 LEI · 335800N8M7W5JDTAHR68 BSE.NS Manufacturing
Open in API
Filings indexed 1,256 across all filing types
Latest filing 2025-10-09 Regulatory Filings
Country IN India
Listing BSE.NS ASTRAZEN

About AstraZeneca Pharma India Ltd.

https://www.astrazeneca.com/content/az-…

AstraZeneca Pharma India Ltd. is a science-led biopharmaceutical organization dedicated to the discovery, development, and commercialization of innovative prescription medicines. The company focuses on core therapeutic areas including Oncology, Cardiovascular, Renal & Metabolism, Respiratory & Immunology, and Rare Disease. Its product portfolio includes advanced treatments such as Tagrisso, Lynparza, and Imfinzi for various cancers, as well as Forxiga and Brilinta for metabolic and cardiovascular conditions. The company utilizes a robust global research pipeline to address complex medical challenges and improve patient outcomes. Through clinical research and specialized healthcare solutions, it delivers transformative therapies designed to treat chronic and life-threatening diseases. The organization is characterized by its commitment to scientific excellence and the delivery of high-value medical interventions.

Recent filings

Filing Released Lang Actions
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a certificate issued pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, confirming compliance. It is addressed to stock exchanges and signed by the company secretary. The document length is short (1360 characters) and it is a compliance certificate rather than a financial report or announcement of financial results. It does not contain financial data or detailed report content. This fits the description of a Regulatory Filing (RNS), which includes officer certifications and compliance confirmations.
2025-10-09 English
Product launch
Regulatory Filings Classification · 95% confidence The document is an intimation letter addressed to stock exchanges (BSE and NSE) under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015. It informs about the receipt of permission from a regulatory authority (Central Drugs Standard Control Organisation) for an additional indication of a pharmaceutical product. The content is a regulatory announcement about a material event affecting the company, not a financial report, earnings release, or management discussion. The document length is short (1856 characters) and it is an announcement of a regulatory approval event. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-10-03 English
Please find the enclosed intimation of the Company as per the captioned subject for your reference.
Regulatory Filings
2025-10-03 English
General Updates
Board/Management Information Classification · 100% confidence The document is a formal notification addressed to stock exchanges (BSE and NSE) regarding the resignation of a senior executive, Mr. Pankaj Jain, Head – Legal at AstraZeneca Pharma India Limited. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically Regulation 30, which pertains to disclosure of material events including changes in key managerial personnel. The content includes details about the resignation, effective date, and a brief note on the search for a replacement. There are no financial statements, earnings data, or report attachments. The document is clearly an announcement of a management change rather than a full management report or annual report. Therefore, it fits the category of Board/Management Information (MANG). The document length is short (2061 characters), and it is not an announcement of a report publication but a direct disclosure of management change.
2025-09-19 English
Pursuant to Regulation 30 of SEBI Listing Regulations, we would like to inform that Mr. Pankaj Jain, currently Head-Legal at AstraZeneca Pharma India Limited has decided to pursue his career ....
Regulatory Filings
2025-09-19 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges notifying the closure of the trading window in compliance with insider trading regulations. It mentions the closure period related to the upcoming declaration of unaudited financial results but does not contain any financial data or results itself. The document is short (1272 characters) and serves as an announcement rather than a report. It is not a financial report, earnings release, or management discussion. The content fits the category of a Regulatory Filing (RNS) as it is a compliance-related announcement that does not fit other specific categories.
2025-09-12 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.